How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

30,753 results for

Drug Withdrawal

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

, Los Angeles Los Angeles, CA Nancy Lane, M.D. Director and Distinguished Professor Center for Musculoskeletal Health and Department of Internal Medicine University of California at Davis, School of Medicine Sacramento, California Jasvinder Singh, M.D., M.P.H. Division of Rheumatology University of Alabama Birmingham, AL vii Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Structured Abstract Objective. To summarize the effects of long-term (...) Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Comparative Effectiveness Review Number 218 RComparative Effectiveness Review Number 218 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600

2019 Effective Health Care Program (AHRQ)

2. Felbamate add-on therapy for drug-resistant focal epilepsy. (Abstract)

Felbamate add-on therapy for drug-resistant focal epilepsy. This is an updated version of the Cochrane Review previously published in 2017.Epilepsy is a chronic and disabling neurological disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy have seizures that are resistant to currently available antiepileptic drugs and require treatment with multiple antiepileptic drugs in combination. Felbamate is a second-generation antiepileptic drug that can be used (...) as add-on therapy to standard antiepileptic drugs.To evaluate the efficacy and tolerability of felbamate versus placebo when used as an add-on treatment for people with drug-resistant focal-onset epilepsy.For the latest update we searched the Cochrane Register of Studies (CRS Web), MEDLINE, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP), on 18 December 2018. There were no language or time restrictions. We reviewed the reference lists of retrieved studies

2019 Cochrane

3. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients

Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients LABORATORY MEDICINE PRACTICE GUIDELINES EDITED BY LORALIE J. LANGMAN AND PAUL J. JANNETTO Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Co-Sponsored byLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients Loralie J. Langman Committee Chair Department of Laboratory Medicine and Pathology Mayo Clinic (...) References 101 Table of ContentsLABORATORY MEDICINE PRACTICE GUIDELINES Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients 5 Executive Summary Introduction The American Association for Clinical Chemistry (AACC) Acad- emy, formerly the National Academy of Clinical Biochemistry (NACB), has developed a laboratory medicine practice guidelines (LMPG) for using laboratory tests to monitor drug therapy in pain management patients. The scope and purpose of this guideline

2018 American Academy of Pain Medicine

4. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina

2018 Effective Health Care Program (AHRQ)

5. Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

Diabetes Canada, have acknowledged that there may be a role for adjunctive therapy in some T1D patients. 10,23,40 In the US, pramlintide acetate injection (Symlin) is the only noninsulin drug approved for adjunctive treatment of T1D. 13,29 Metformin, a T2D medication, is mentioned by Diabetes Canada and the American Diabetes Association for off-label use to reduce insulin requirements and total cholesterol/low-density lipoprotein ratios, 10,17,23 with the caveat that it does not improve hemoglobin A1C (...) Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? | CADTH.ca CADTH Document Viewer Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? Table of Contents Search this document Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes? January 2018 Summary There are two major

2018 CADTH - Issues in Emerging Health Technologies

6. New Drugs for Type 2 Diabetes: Second-Line Therapy — Recommendations Report

therapies for second- and third-line treatment of type 2 diabetes. Since 2013, several new drugs and a new medication class (sodium-glucose cotransporter-2 [SGLT-2] inhibitors) have been released on the market in Canada. During the same period, CADTH Common Drug Review has provided multiple recommendations in technology assessments of individual drugs for type 2 diabetes. Given the evolving landscape of the treatment of type 2 diabetes, an update of the previous review has been undertaken. This document (...) on varying background therapies and pragmatically allowed for continuation of whatever the existing background therapy was at baseline. Background therapies were no treatment (i.e., they were drug-naive and starting the study intervention); monotherapy (they were taking a single antidiabetic medication or insulin and added the study intervention to that therapy); dual therapy; and combinations of more than two therapies. There were limited data regarding proportions of background therapy for the enrolled

2017 CADTH - Plasma Products

7. New Drugs for Type 2 Diabetes: Second-Line Therapy — Recommendations Report

therapies for second- and third-line treatment of type 2 diabetes. Since 2013, several new drugs and a new medication class (sodium-glucose cotransporter-2 [SGLT-2] inhibitors) have been released on the market in Canada. During the same period, CADTH Common Drug Review has provided multiple recommendations in technology assessments of individual drugs for type 2 diabetes. Given the evolving landscape of the treatment of type 2 diabetes, an update of the previous review has been undertaken. This document (...) on varying background therapies and pragmatically allowed for continuation of whatever the existing background therapy was at baseline. Background therapies were no treatment (i.e., they were drug-naive and starting the study intervention); monotherapy (they were taking a single antidiabetic medication or insulin and added the study intervention to that therapy); dual therapy; and combinations of more than two therapies. There were limited data regarding proportions of background therapy for the enrolled

2017 CADTH - Plasma Products

8. Functional Family Therapy (FFT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Full Text available with Trip Pro

Functional Family Therapy (FFT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Functional Family Therapy (FFT) for Young People in Treatment for Non‐opioid Drug Use: A Systematic Review - Filges - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Functional Family Therapy (FFT) for Young People (...) version of this article with your friends and colleagues. Copy URL Share a link Share on 1 The terms ‘use’, ‘abuse’ and ‘dependence’ are often used interchangeably and refer to an addiction stage of non‐medical drug usage. of the kind that persists beyond the experimentation phase is a severe problem worldwide ( ). Abuse of non‐opioid drugs such as cannabis, amphetamine and cocaine is strongly associated with a broad range of negative health implications such as traffic accidents, sexually transmitted

2015 Campbell Collaboration

9. Family Behavior Therapy (FBT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Full Text available with Trip Pro

Family Behavior Therapy (FBT) for Young People in Treatment for Non?opioid Drug Use: A Systematic Review Family Behavior Therapy (FBT) for Young People in Treatment for Non‐opioid Drug Use: A Systematic Review - Lindstrøm - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Family Behavior Therapy (FBT) for Young People in Treatment (...) ‐medical drug usage. that persists beyond curious experimentation is a severe problem worldwide (United Nations Office of Drugs and Crime . Use of non‐opioid drugs such as cannabis, amphetamine and cocaine is strongly associated with a range of health and social problems, including delinquency, poor scholastic attainment, fatal automobile accidents, suicide and other individual and public calamities ( ; ; ; Office of National Drug Control Policy ; ). More than 20 million of the 12 to 25 year‐olds

2015 Campbell Collaboration

10. Cognitive?Behavioural Therapies for Young People in Outpatient Treatment for Non?Opioid Drug Use: A Systematic Review Full Text available with Trip Pro

Cognitive?Behavioural Therapies for Young People in Outpatient Treatment for Non?Opioid Drug Use: A Systematic Review Cognitive‐Behavioural Therapies for Young People in Outpatient Treatment for Non‐Opioid Drug Use: A Systematic Review - Filges - 2015 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Cognitive‐Behavioural Therapies (...) below to share a full-text version of this article with your friends and colleagues. Copy URL Share a link Share on 1 The terms use, abuse and dependence are used interchangeably throughout the review and refer to an addiction stage of non‐medical usage. that persists beyond curious experimentation is a severe problem worldwide ( ). Drugs such as cannabis, amphetamines, ecstasy and cocaine, referred to in this review as non‐opioids 2 Use of ketamine, nitrous oxide and inhalants, e.g. glue and petrol

2015 Campbell Collaboration

11. Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their

by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Raltegravir + Lamivudine Drug: Raltegravir Raltegravir (1200 mg once a day) Drug: Lamivudine Lamivudine (300 mg once a day) Outcome Measures Go to Primary Outcome Measures : Therapeutic failure [ Time Frame: 48 weeks ] therapeutic failure at week 48, includes virological failure, change in treatment for any reason, consent withdrawal, loss to follow-up or death Secondary (...) Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug

2017 Clinical Trials

12. High Rate of Drug-Free Remission After Induction Therapy With Golimumab in Early Peripheral Spondyloarthritis. Full Text available with Trip Pro

prospectively followed up to assess the rate of sustained drug-free clinical remission and clinical relapse.Eighty-two percent of patients (49 of 60) fulfilled sustained clinical remission criteria after a regimen of induction therapy with golimumab. The majority of patients already reached this status at week 24 (n = 30), with an additional 11 and 8 patients at weeks 36 and 48, respectively. All patients had a follow-up period of at least 18 months after drug withdrawal. Fifty-three percent of patients (26 (...) of 49) still have drug-free remission of their disease. Inability to sustain drug-free remission was associated with the presence of psoriasis and polyarticular disease (swollen joint count >5).Anti-TNF treatment in very early peripheral SpA results in a remarkably high rate of sustained clinical remission. More than 50% of patients continue to have remission of their disease after withdrawal of therapy, which highlights a defined window of opportunity permitting induction of drug-free remission.©

2019 Arthritis & rheumatology (Hoboken, N.J.) Controlled trial quality: uncertain

13. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. (Abstract)

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Combination treatment with azathioprine for 6-12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics. However, optimised infliximab monotherapy with proactive dose escalations in case of low trough levels is a safer but under-studied alternative.To compare the clinical success and infliximab (...) strategy at year 1. At the end of follow-up, when azathioprine had been discontinued for a median of 14 [IQR: 3-33] months, these differences disappeared.In this study, optimised infliximab monotherapy was as clinically effective as combination therapy but was associated with significantly higher infliximab consumption. The infliximab-sparing effect disappeared after azathioprine withdrawal.© 2019 John Wiley & Sons Ltd.

2019 Alimentary Pharmacology & Therapeutics

14. Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka Zambia. (Abstract)

Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka Zambia. HIV viral load (VL) and resistance testing are limited in sub-Saharan Africa, so individuals may have prolonged time on failing first-line antiretroviral therapy (ART). Our objective was to describe the evolution of drug resistance mutations among adults failing first-line ART in Zambia.We analyzed data from a trial of VL monitoring in Lusaka, Zambia. From 2006 to 2011, 12 (...) randomized sites provided either routine VL monitoring (intervention) or discretionary (control) after ART initiation. Samples were collected prospectively following the same schedule in each arm but analyzed retrospectively in the control group. For those with virologic failure (VF) (>400 copies/mL), HIV genotyping was performed retrospectively on baseline (BL) and on all subsequent specimens until censored due to study completion, withdrawal, or death.Of 1,973 enrollees, 165 (8.4%) developed VF. 464

2019 Antiviral Therapy

15. Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non?Opioid Drug Use: A Systematic Review Full Text available with Trip Pro

Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non?Opioid Drug Use: A Systematic Review Brief Strategic Family Therapy (BSFT) for Young People in Treatment for Non‐Opioid Drug Use: A Systematic Review - Lindstrøm - 2013 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Brief Strategic Family Therapy (BSFT (...) this review and refer to an addiction stage of non‐medical drug usage; this definition implies that the term ‘use’ refers to the consumption of drugs beyond experimentation and into addiction. of the kind that persists beyond the experimentation phase is a severe problem worldwide (United Nations Office of Drugs and Crime (UNODC), 2010), and the use of non‐opioid drugs such as cannabis, amphetamines and cocaine is strongly associated with a broad range of health and social problems, including delinquency

2013 Campbell Collaboration

16. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction. (Abstract)

Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction. A relationship between iodine intake and the effectiveness of antithyroid drug (ATD) therapy for Graves' disease (GD) has been suggested, and strict restriction of iodine intake has been tried in the treatment of GD in some studies. However, it is unclear whether dietary iodine supplementation improves the prognosis of ATD therapy for GD (...) . This study aimed to clarify whether optimal iodine supplementation during antithyroid drug therapy for GD is associated with lower recurrence rates than iodine restriction.This was a prospective randomized trial of newly diagnosed patients with GD. Patients with newly diagnosed GD were recruited. After ATD therapy and strict dietary iodine restriction for 1 month, patients (n = 459) were randomly assigned to iodine-supplemented and iodine-restricted groups. After exclusion, 405 patients finally completed

2018 Clinical endocrinology Controlled trial quality: uncertain

17. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study Full Text available with Trip Pro

Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study Little evidence is available for head-to-head comparisons of psychosocial interventions and pharmacological interventions in psychosis. We aimed to establish whether a randomised controlled trial of cognitive behavioural therapy (CBT) versus antipsychotic drugs versus a combination of both would be feasible in people (...) analyses were done by intention to treat; safety analyses were done on an as-treated basis. The study was prospectively registered with ISRCTN, number ISRCTN06022197.Of 138 patients referred to the study, 75 were recruited and randomly assigned-26 to CBT, 24 to antipsychotics, and 25 to antipsychotics plus CBT. Attrition was low, and retention high, with only four withdrawals across all groups. 40 (78%) of 51 participants allocated to CBT attended six or more sessions. Of the 49 participants randomised

2018 The Lancet. Psychiatry Controlled trial quality: predicted high

18. Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Full Text available with Trip Pro

Acute liver failure induced by idiosyncratic reaction to drugs: challenges in diagnosis and therapy. Acute liver failure (ALF) requires urgent attention to identify etiology and determine prognosis, in order to assess likelihood of survival or need for transplantation. Identifying idiosyncratic drug-induced liver injury (iDILI) may be particularly difficult, but the illness generally follows a subacute course, allowing time to assess outcome and find a liver graft if needed. Not all drugs (...) that cause iDILI lead to ALF; the most common are antibiotics including anti-tuberculous medications, non-steroidal anti-inflammatory agents and herbal and dietary supplements (HDS). Determining causality remains challenging particularly if altered mentation is present; identifying the causative agent depends in part on knowing the propensity of the drugs that have been taken in the proper time interval, plus excluding other causes. In general, iDILI that reaches the threshold of ALF will more often than

2017 Liver International

19. A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer Full Text available with Trip Pro

diplopia, ptosis, fatigue, weakness, and an inflammatory myopathy affecting the extraocular muscles requiring hospitalisation. Electromyography (EMG) testing and muscle biopsy suggested inflammatory myopathy without sign of myasthenia. Within 1 month of withdrawal of cancer therapies and initiation of oral steroid therapy, ocular and systemic symptoms had resolved. This notable adverse effect has not been previously described for these drugs administered singly or in combination, and ophthalmologists (...) A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer Recently developed anti-tumour therapies targeting immune checkpoints include tremelimumab and durvalumab. These agents have incompletely characterised side effect profiles. The authors report a 68-year-old man treated for non-small cell lung cancer (NSCLC) with a combination of tremelimumab and durvalumab. After treatment he developed

2017 Neuro-Ophthalmology

20. Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence Full Text available with Trip Pro

Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence Graves' disease (GD) is the most common cause of hyperthyroidism worldwide. Current therapeutic options for GD include antithyroid drugs (ATD), radioactive iodine, and thyroidectomy. ATD treatment is generally well accepted by patients and clinicians due to some advantages including normalizing thyroid function in a short time, hardly causing hypothyroidism, and ameliorating immune disorder while avoiding radiation (...) . Levothyroxine administration after successful ATD treatment was not recommended. The addition of immunosuppressive drugs might be helpful to decrease the recurrence rate of GD patients after ATD withdrawal, whereas further studies are needed to address the safety and efficacy. This paper reviewed the current knowledge of ATD treatment and mainly focused on influencing factors for recurrence in GD patients with ATD treatment.

2017 International journal of endocrinology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>